Healthequity AI Stock Analysis
Want to see HQY full AI Analyst Report?
Healthequity (HQY) AI Stock Analysis
Healthequity
(NASDAQ:HQY)
The score is supported primarily by strong financial performance (profitability turnaround, expanding margins, and robust free cash flow) and a constructive earnings update with raised FY2027 guidance and continued buybacks. Offsetting these strengths, technicals are notably weak with the stock in a downtrend despite oversold readings, and valuation remains somewhat premium (P/E ~31) without dividend support.
Healthequity (HQY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $8.05B
- Dividend Yield
- ―
- Average Volume (3M)
- 884.44K
- Price to Earnings (P/E)
- 34.8
- Beta (1Y)
- 0.73
- Revenue Growth
- 7.33%
- EPS Growth
- 65.97%
- Country
- US
- Employees
- 2,814
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Healthequity Business Overview & Revenue Model
Company Description
Headquartered in Draper, Utah, and established in 2002, HealthEquity, Inc. furnishes technology-powered service platforms to both individual consumers and employers across the United States. The company provides cloud-based solutions designed to assi...
How the Company Makes Money
HealthEquity primarily makes money through fees for administering and servicing benefit accounts and through income earned on the assets held in those accounts. 1) Service fees (benefits account administration) - HealthEquity charges administration a...
Healthequity Earnings Call Summary
The call conveyed strong operational and financial momentum: accelerated revenue growth, record gross profit and adjusted EBITDA margin expansion, raised fiscal 2027 guidance, robust HSA account and asset growth, meaningful digital and AI-driven efficiency gains, and healthy cash generation enabling share repurchases. Key risks and near-term constraints include marketplace revenue still being immaterial, competitive price pressure on service fees, hedging that limits yield upside, modest total account growth outside HSAs, and a small current share of investing HSA members. Overall, the positive execution, raised guidance, and margin durability materially outweigh the noted challenges.
Q2-2027 Updates
Positive Updates
Negative Updates
Company Guidance
HealthEquity raised its fiscal 2027 outlook, now expecting revenue of $1.411–1.421 billion, GAAP net income of $242–248 million (or $2.88–$2.96 per share), non‑GAAP net income of $392–398 million (or $4.66–$4.73 per share on an estimated 84 million shares), and adjusted EBITDA of $628–636 million; management assumes a GAAP and non‑GAAP tax rate of ~25%. They expect average HSA cash yield of 3.85–3.90% in FY27 and noted $2.3 billion of HSA cash repricing remaining in FY27, $460 million of forward Treasury contracts matured in Q2, $3.0 billion of outstanding forward contracts effectively locking a ~3.9% five‑year Treasury rate (net of costs) across FY27–29, and small forward hedges placed post‑quarter for enhanced‑rate repricings over the next 12–18 months. The company closed the quarter with $256 million of cash, generated $136 million of operating cash flow, had ~$931 million of debt outstanding (net of issuance costs), repurchased about $108 million of shares in Q2 at an average price below $90 and has roughly $948 million remaining under its $1.6 billion repurchase authorization; the guidance reflects continued funding of growth initiatives, planned share repurchases, potential revolver paydowns, and preserved capacity for opportunistic M&A.
Healthequity Financial Statement Overview
Summary
Strong fundamentals driven by a clear shift to durable profitability, meaningful margin expansion (TTM net margin ~17% and gross margin ~73%), and excellent cash generation (TTM FCF ~$472M with strong cash-to-earnings coverage). Main risks are inconsistency in reported debt levels between FY2026 annual vs TTM and some near-term variability in margins/FCF growth that should be monitored.
Income Statement
86Very PositiveBalance Sheet
72PositiveCash Flow
84Very Positive| Breakdown | TTM | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.36B | 1.31B | 1.20B | 999.59M | 861.75M | 756.56M |
| Gross Profit | 1.02B | 913.12M | 692.58M | 529.87M | 395.50M | 340.92M |
| EBITDA | 495.07M | 489.22M | 337.54M | 282.42M | 171.53M | 102.97M |
| Net Income | 236.49M | 215.20M | 96.70M | 55.71M | -26.14M | -44.29M |
Balance Sheet | ||||||
| Total Assets | 3.27B | 3.38B | 3.45B | 3.16B | 3.09B | 3.11B |
| Cash, Cash Equivalents and Short-Term Investments | 256.00M | 318.93M | 295.95M | 403.98M | 254.27M | 225.41M |
| Total Debt | 971.02M | 1.00B | 1.11B | 933.14M | 994.49M | 1.01B |
| Total Liabilities | 1.28B | 1.27B | 1.33B | 1.13B | 1.19B | 1.25B |
| Stockholders Equity | 1.99B | 2.11B | 2.11B | 2.04B | 1.90B | 1.85B |
Cash Flow | ||||||
| Free Cash Flow | 471.67M | 455.13M | 337.77M | 196.75M | 31.52M | 3.91M |
| Operating Cash Flow | 490.18M | 457.09M | 339.86M | 242.83M | 150.65M | 141.00M |
| Investing Cash Flow | -59.64M | -47.14M | -505.45M | -46.07M | -119.13M | -639.25M |
| Financing Cash Flow | -479.00M | -386.98M | 57.57M | -47.04M | -2.67M | 394.86M |
Healthequity Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HQY, the sentiment is Neutral. The current price of 97.38 is below the 20-day moving average (MA) of 102.58, above the 50-day MA of 96.57, and above the 200-day MA of 90.29, indicating a neutral trend. The MACD of 0.91 indicates Positive momentum. The RSI at 43.34 is Neutral, neither overbought nor oversold. The STOCH value of 11.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HQY.
Healthequity Risk Analysis
Healthequity disclosed 43 risk factors in its most recent earnings report. Healthequity reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksHealthequity Peers Comparison
Overall Rating
HNGE81Outperform
WAY76Outperform
HQY73Outperform
OMDA69Neutral
GDRX64Neutral
TDOC56Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $8.79B | 51.97 | 50.47% | ― | 49.86% | ― | |
| 76Outperform | $5.21B | 38.70 | 3.41% | ― | 21.43% | 9.80% | |
| 73Outperform | $8.05B | 34.78 | 11.43% | ― | 7.33% | 65.97% | |
| 69Neutral | $775.47M | 52.54 | 5.67% | ― | 43.34% | ― | |
| 64Neutral | $1.03B | 57.41 | 2.61% | ― | -1.83% | -48.77% | |
| 56Neutral | $1.42B | -9.06 | -11.63% | ― | -2.38% | 32.73% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HQY | Healthequity Inc | 97.38 | -4.53 | -4.45% | |
| TDOC | Teladoc Inc. | 7.79 | 0.83 | 11.93% | |
| GDRX | Goodrx Holdings, Inc. | 3.02 | 0.31 | 11.44% | |
| WAY | Waystar Holding Corp. | 27.09 | -8.65 | -24.20% | |
| HNGE | Hinge Health, Inc. Class A | 108.10 | 62.11 | 135.05% | |
| OMDA | Omada Health, Inc. | 12.50 | -6.10 | -32.80% |
Healthequity Corporate Events
HealthEquity Announces Chief Commercial Officer Leadership Change
NeutralHealthEquity, Inc. terminated the employment of Chief Commercial Officer Michael Fiore without cause, effective October 5, 2026, and plans to redistribute the CCO’s responsibilities among other members of its management team. Under the terms of his e...
HealthEquity adds Moody’s CFO Heuland to board
PositiveOn September 24, 2026, HealthEquity appointed Moody’s Corporation Chief Financial Officer Noémie Heuland to its board of directors, expanding the board from ten to eleven members, nine of whom are independent. Heuland will serve on the Audit and Risk...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 30, 2026
